An official website of the United States government
Here's how you know
A .mil website belongs to an official U.S. Department of Defense organization in the United States.
A lock (lock ) or https:// means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

Home : Media : News : News Article View
NEWS | Jan. 10, 2023

DOD Aims to Shield Warfighters from Novel Biological Agents

By David Vergun DOD News

WASHINGTON -- The Department of Defense is modernizing its approach for developing medical countermeasures to protect warfighters from novel biological agents.

This is made clear in a new document, "Approach for Research, Development and Acquisition of Medical Countermeasures and Test Products," which was recently published by the Office of the Deputy Assistant Secretary of Defense for Chemical and Biological Defense. This office oversees the Department of Defense's Chemical and Biological Defense Program. The CBDP's mission is to anticipate future threats and deliver capabilities that enable the Joint Force to fight and win in CB-contested environments.

The CBDP has always prioritized medical countermeasures, which consist of vaccines, medical tests and drugs. "No matter how good our boots, suits, gloves and masks perform, there's always going to be the risk that our warfighters don't necessarily have their equipment on when they need it. So having medical countermeasures as an added layer for protection makes sense," Dr. Kevin Wingerd, CBDP's medical director, said.

What has changed is the nature of the threat.

"The convergence of different sciences and technologies is transforming the biological threat landscape," Wingerd said. "In particular, it has created a nearly limitless number of potential threats we must defend against."

This contrasts to the past, when DOD developed medical countermeasures against a defined list of specific threats, typically ones adversaries had already weaponized. But this "one bug, one drug" approach isn't viable in the face of the exponentially larger number of potential threats, including novel ones.

Nor is the Department solely focused on deliberate biological threats. In his Biodefense Vision Memo published in November 2021, Secretary of Defense Lloyd J. Austin III directed the Department to be postured against agents that are naturally occurring as well as those that may have been released accidentally, alongside traditional deliberate ones. The new medical countermeasures approach provides a roadmap to address this more challenging problem set.

Spotlight: Engineering in the DOD

According to the document, nonspecific medical countermeasures will enable warfighters to remain on the battlefield after being exposed to an agent. After that agent has been identified, rapid development of medical countermeasures that eliminate the specific threat will be given to all warfighters, including those newly entering the battle.

Nonspecific medical countermeasures are broad-spectrum acting and are designed to target a set of similar agents, diseases or symptoms. Nonspecific medical countermeasures are particularly vital for novel agents that have no medical countermeasures. Administrating nonspecific medical countermeasures could alleviate symptoms, slow down disease progression and reduce transmission of the agent, allowing troops to remain in the battle with little impairment. While the agent may be suppressed for a given period, a medical countermeasure that targets and eliminates the novel agent is still required.

As Wingerd puts it, "Using nonspecific medical countermeasures allows the agent's effects to be mitigated and the warfighter to remain operational and combat ready, while simultaneously allowing for rapid development of specific medical countermeasures that can be used to completely get rid of the agent and protect incoming warfighters."

To rapidly develop narrow-spectrum medical countermeasures, the CBDP will leverage cutting edge technology including artificial intelligence and machine learning and establish partnerships with known pharmaceutical manufacturers. The CBDP considers manufacturing capacity a strategic challenge, which the new approach addresses as a goal.

"In a response preparedness posture, we need to invest in unique medical infrastructure designed to rapidly produce new vaccines and drugs, and leverage existing medical infrastructure by adapting them to target new agents quickly," Wingerd explained.

"What COVID has certainly taught us is that if that industrial base isn't present, it doesn't matter how good your ideas are, they're just not going to go anywhere," he added, mentioning that partnerships with the interagency, academia and U.S. allies and partners are also critical.

Besides the U.S. Food and Drug Administration, which is the regulating agency for medical countermeasures, Wingerd mentioned the Biomedical Advanced Research and Development Authority and the White House Office of Science and Technology Policy as key CBDP interagency partners. Pointing to the recently updated National Biodefense Strategy, Wingerd said, "This effort is really a whole of government approach, and the CBDP's new approach aligns with and supports the NBS."

He added that he expects new advances in medical countermeasures to bear fruit beginning as early as next year, with more to follow.


Like Us
Follow Us



U.S., South Korea Want Peace in Indo-Pacific
Jan. 31, 2023 - Secretary of Defense Lloyd J. Austin III stressed that the goal of the U.S.-South Korean alliance is peace — not conflict — following meetings in Seoul, South Korea, today.The secretary made the remarks at a news conference...

U.S. Army Advisors Strengthen Partnership in Thailand
Sgt. 1st Class Justin Babb takes part in close quarters battle rehearsals with members of the Royal Thai Army. Babb is part of an SFAB Team assigned to Force Package 23-1, the 5th SFAB's forward-deployed element.
Jan. 31, 2023 - NAKHON NAYOK, Thailand – Three Advisor Teams from 2nd Battalion, 5th Security Force Assistance Brigade partnered with the Royal Thai Army across Thailand during a multi-month rotation into theater beginning in October 2022...

U.S. Indo-Pacific Commander Travels to Papua New Guinea
Indo-Pacific Command, traveled to Papua New Guinea
Jan. 30, 2023 - PORT MORESBY, Papua New Guinea -- Admiral John C. Aquilino, Commander of U.S. Indo-Pacific Command, traveled to Papua New Guinea January 29-30 to underscore the U.S. commitment to advance shared interests toward building a...

Austin Looks to Build on Strengths of Alliances With South Korea, the Philippines
In this file photo, an F/A-18E Super Hornet from the “Blue Diamonds” of Strike Fighter Squadron (VFA) 146 approaches for an arrested landing aboard the aircraft carrier USS Nimitz (CVN 68). Nimitz is in 7th Fleet conducting routine operations. 7th Fleet is the U.S. Navy's largest forward-deployed numbered fleet, and routinely interacts and operates with 35 maritime nations in preserving a free and open Indo-Pacific region.
Jan. 30, 2023 - WASHINGTON -- The security environment in the Indo-Pacific is growing more complex and Secretary of Defense Lloyd J. Austin III will meet with allies in the Republic of Korea and the Philippines to continue efforts to...

Australia, Japan, U.S. Stand Up Multinational Task Force for Cope North
Jan. 30, 2023 - JOINT BASE PEARL HARBOR-HICKAM, Hawaii -- Air forces from Australia, Japan, and the United States have begun arriving in Guam to establish the command and control multinational task force for Cope North (CN) 2023, which runs...